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Abstract: Low-density lipoprotein (LDL) cholesterol concentration has been the prime index of 
cardiovascular disease risk and the main target for therapy. However, several lipoprotein ratios 
or “atherogenic indices” have been defined in an attempt to optimize the predictive capacity of 
the lipid profile. In this review, we summarize their pathophysiological aspects, and highlight 
the rationale for using these lipoprotein ratios as cardiovascular risk factors in clinical practice, 
specifying their cut-off risk levels and a target for lipid-lowering therapy. Total/high-density 
lipoprotein (HDL) cholesterol and LDL/HDL cholesterol ratios are risk indicators with greater 
predictive value than isolated parameters used independently, particularly LDL. Future 
recommendations regarding the diagnosis and treatment of dyslipidemia, including instruments 
for calculating cardiovascular risk or action guidelines, should include the lipoprotein ratios 
with greater predictive power which, in view of the evidence-based results, are none other than 
those which include HDL cholesterol.
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Introduction
Estimation of cardiovascular risk has become the cornerstone of cardiovascular 
prevention. Although atherogenesis is a multifactorial process, abnormalities in 
lipoprotein metabolism are one of the key factors, representing around 50% of 
the population-attributable risk of developing cardiovascular disease.1 Despite of 
the considerable progress made in cardiovascular disease management in recent 
decades, there is almost unanimous agreement among epidemiologists and clinicians 
that coronary risk assessment based exclusively on low-density lipoprotein (LDL) 
cholesterol is not optimal,2 particularly in individuals at intermediate risk.3 Efforts 
have been made in seeking emergent or new cardiovascular risk factors to improve 
cardiovascular disease prediction.1 However, it must be emphasized that in an attempt 
to optimize the predictive capacity of the lipid profile, several lipoprotein ratios or 
“atherogenic indices” have been defined. These ratios can provide information on risk 
factors difficult to quantify by routine analyses and could be a better mirror of the 
metabolic and clinical interactions between lipid fractions. Since lipoprotein ratios 
are under-used in cardiovascular prevention, but can add to risk assessment, in this 
review, we briefly summarize their physiological and pathophysiological aspects. 
Furthermore, we highlight the rationale for using these lipoprotein ratios as cardio-
vascular risk factors in clinical practice, specifying their cut-off risk levels and a target 
for lipid-lowering therapy (Table 1).Vascular Health and Risk Management 2009:5 758
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Total cholesterol/HDL cholesterol 
and LDL/HDL cholesterol ratios
The total/high-density lipoprotein (HDL) cholesterol ratio, 
known as the atherogenic or Castelli index and the LDL/HDL 
cholesterol ratio are two important components and indica-
tors of vascular risk, the predictive value of which is greater 
than the isolated parameters. In this respect, an increase 
in total cholesterol concentration, and specifically LDL 
cholesterol, is an atherogenic lipid marker, whereas reduced 
HDL cholesterol concentration is correlated with numerous 
risk factors, including the components of the metabolic 
syndrome, and probably involves independent risk.4 When 
total cholesterol, HDL cholesterol, and total/HDL cholesterol 
ratio are compared between an apparently healthy popula-
tion and myocardial infarction survivors, the total/HDL 
cholesterol ratio is found to present less superposition of 
populations.5 This illustrates the high discriminatory power 
for coronary heart disease presented by the total/HDL 
cholesterol ratio, as well as its great predictive capacity. 
The value of this parameter when the lipid profile is within 
desirable range should be emphasized. For example, total 
cholesterol of  231 mg/dL (5.89 mmol/L) and HDL cholesterol 
of 42 mg/dL (1.09 mmol/L) gives a total/HDL cholesterol 
ratio of 5.5, which indicates moderate atherogenic risk.6 
On the other hand, with the same level of total cholesterol, 
if HDL cholesterol were 60 mg/dL (1.55 mmol/L), the ratio 
would be 3.8. As total cholesterol/HDL ratio is considered a 
more sensitive and specific index of cardiovascular risk than 
total cholesterol, the Canadian working group has chosen 
this lipid ratio as a secondary goal of theraphy.7
The LDL/HDL cholesterol ratio appears to be as use-
ful as the total/HDL cholesterol ratio. Their similarity can 
be explained by the fact that approximately two thirds of 
plasma cholesterol are found in LDL and, consequently, 
total and LDL cholesterol are closely related. Like the 
total/HDL cholesterol ratio, LDL/HDL cholesterol may 
have more predictive power if triglyceridemia is taken into 
account.8 Although, the increase in these ratios predicted a 
greater cardiovascular risk in a wide range of cholesterol or 
triglyceride concentrations, the risk is significantly higher 
when hypertriglyceridemia is present, as shown by the 
Helsinki Heart Study.9
However, it is clear than when there is no reliable 
calculation of LDL cholesterol, as when triglyceridemia 
exceeds 300 mg/dL (3.36 mmol/L), it is preferable to use the 
total/HDL cholesterol ratio; furthermore, the very-low-density 
lipoprotein (VLDL) fraction shows cholesterol enrichment 
in individuals with high triglyceride concentrations, and 
thus the LDL/HDL cholesterol ratio may underestimate the 
magnitude of the lipoprotein abnormality in these patients.
Individuals with a high total/HDL cholesterol or 
LDL/HDL cholesterol ratio have greater cardiovascular 
risk owing to the imbalance between the cholesterol carried 
by atherogenic and protective lipoproteins. This may be due 
to an increase in the atherogenic component contained in the 
numerator, a decrease in the anti-atherosclerotic trait of the 
denominator, or both.10
Some studies have calculated inverse ratios, ie, HDL/total 
cholesterol and HDL/LDL cholesterol. Although their 
predictive value is identical but in the opposite order, few 
authors suggest they more clearly express the proportion of 
HDL cholesterol (protective) compared with the rest.8
ApoB/ApoA-I ratio
Apolipoprotein (apo) B represents most of the protein 
content in LDL and is also present in intermediate-density 
lipoproteins (IDL) and VLDL. ApoA-I is the principal 
apolipoprotein in HDL. Both apolipoproteins, therefore, sepa-
rately provide information for detecting high-risk individuals. 
ApoA-I is also believed to be a more reliable parameter 
for measuring HDL than cholesterol content since it is not 
subject to variation. Therefore, the apoB/apoA-I ratio is also 
Table 1 Risk categories and target levels for total cholesterol/HDL-C, LDL-C/HDL-C and apoB/apoA-i ratios, in primary and secondary 
prevention, stratified by gender6,7,14
Ratio Primary prevention Secondary prevention*
Risk level Target Risk level Target
Men Women Men Women Men Women Men Women
TC/HDL-C 5.0 4.5 4.5 4.0 4.0 3.5 3.5 3.0
LDL-C/HDL-C 3.5 3.0 3.0 2.5 3.0 2.5 2.5 2.0
ApoB/ApoA-i 1.0 0.9 0.9 0.8 0.8 0.7 0.7 0.6
Note: *Or equivalent risk situation.
Abbreviations: Apo, apolipoprotein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol;   TC, total cholesterol.Vascular Health and Risk Management 2009:5 759
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highly valuable for detecting atherogenic risk, and there is 
currently sufficient evidence to demonstrate that it is better 
for estimating vascular risk than the total/HDL cholesterol 
ratio.11–14 The apoB/apoA-I ratio was stronger than the total 
cholesterol/HDL holesterol and LDL/HDL cholesterol ratios 
in predicting risk.11 Furthermore, Walldius and colleagues 
have reported that addition of lipids, lipoproteins or any 
cholesterol ratio to apoB/apoA-I in risk models did not further 
improve the strong predictive value of apoB/apoA-I.13
This ratio reflects the balance between two completely 
opposite processes (Figure 1): transport of cholesterol to 
peripheral tissues, with its subsequent arterial internalization, 
and reverse transport to the liver.15 Figure 2 shows that the 
greater the apoB/apoA-I ratio, the larger will be the amount of 
cholesterol from atherogenic lipoproteins circulating through 
the plasma compartment and likely to induce endothelial 
dysfunction and trigger the atherogenic process. On the other 
hand, a lower apoB/apoA-I ratio will lead to less vascular 
aggression by plasma cholesterol and increased and more 
effective reverse transport of cholesterol, as well as other 
beneficial effects, thereby reducing the risk of cardiovascular 
disease.
Logarithmic transformation  
of the triglyceride/HDL cholesterol 
molar concentration ratio
The association between triglycerides and HDL cholesterol 
reflected by this ratio depicts the balance between atherogenic 
and protective lipoproteins. Known as the atherogenic 
plasma index, it shows a positive correlation with the HDL 
esterification rate (FERHDL) and an inverse correlation 
with LDL size.16 Therefore, the phenotype of LDL and 
HDL particles is clearly synchronized with the FERHDL. 
Hypoalphalipoproteinemia and hypertriglyceridemia both 
induce an increase in the percentage of small HDL and 
small, dense LDL particles. Ultimately, the simultaneous 
use of triglycerides and HDL cholesterol in this ratio reflects 
the complex interactions of lipoprotein metabolism overall 
and can be useful for predicting plasma atherogenicity.17 
An atherogenic plasma index [log (triglycerides/HDL 
cholesterol)] over 0.5 has been proposed as the cut-off point 
indicating atherogenic risk.16
LDL cholesterol/apoB ratio
Although apoB is not an apolipoprotein exclusive to LDL, 
since it is present in other atherogenic lipoprotein fractions 
such as IDL and VLDL, the LDL cholesterol/apoB concentra-
tion ratio provides approximate information on LDL particle 
size. In this respect, it has been suggested that a ratio of less 
than 1.3 would indicate the predominance of LDL particles 
with lower cholesterol content, consistent with small, dense 
LDL particles.18 However, a study comparing LDL particle 
size determination by gradient-gel electrophoresis with the 
LDL cholesterol/apoB ratio in healthy and hyperlipidemic 
subjects failed to find a good correlation and did not recom-
mend the use of this ratio as a surrogate LDL size marker.19
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Figure 1 Atherogenic and anti-atherogenic lipoproteins. This diagram shows that there is one single apolipoprotein B (apoB) molecule in each large, buoyant or small, dense 
particle of very-low-density (VLDL), intermediate-density (iDL), and low-density lipoproteins (LDL). Therefore, apoB represents the total number of potentially atherogenic 
particles.   Apolipoprotein A-i (apo A-i) is the principal protein component in high-density lipoproteins (HDL) and is responsible for starting reverse cholesterol transport. The 
balance between apoB and apoA-i is indicative of cardiovascular risk: the greater the ratio, the greater the risk.
Abbreviations: TG, triglycerides; C, cholesterol; + +, increased risk; - -, reduced risk.Vascular Health and Risk Management 2009:5 760
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Non-HDL cholesterol/HDL 
cholesterol ratio
Non-HDL cholesterol, which is total cholesterol minus 
HDL cholesterol, is a measure of the cholesterol in LDL, 
IDL and VLDL particles. Non-HDL cholesterol has there-
fore been recommended as a secondary therapeutic target 
in individuals with high triglyceride concentration, and it 
has been suggested that it could be a surrogate marker of 
serum apoB concentration in clinical practice. However, 
non-HDL cholesterol is not always strongly associated with 
apoB, particularly in the presence of hypertriglyceridemia.20 
The non-HDL cholesterol/HDL ratio is a lineal combina-
tion of total/HDL cholesterol. Although few studies have 
evaluated this lipoprotein ratio for predicting cardiovascular 
disease, and as it is a lineal combination of the results can be 
assumed to be similar to those of  the total/HDL cholesterol or 
LDL/HDL cholesterol ratios.21
Predictive power of lipoprotein 
ratios for cardiovascular risk
The evidence derived from large observational studies, 
including the Framingham Study,22 the LRCP23 and the 
PROCAM,24,25 suggests that the total/HDL cholesterol ratio is 
a more powerful coronary risk predictor than independently-
used total cholesterol, LDL cholesterol and HDL cholesterol. 
The predictive value for the development of coronary events 
of the baseline total/HDL cholesterol and LDL/HDL choles-
terol ratios in the placebo groups of WOSCOPS,26 AFCAPS/
TexCAPS,27 and 4S28 studies was higher than that of other lipid 
parameters in multivariate analyses. Indeed, the total/HDL 
cholesterol ratio was included in the Framingham equation 
to improve risk prediction.29 The LRC-CPPT study5 analysed 
the ability of the total/HDL cholesterol ratio to predict 
coronary risk and compared it to other lipid metabolism 
variables in three large population-based cohorts: the men 
in the placebo group of the LRCP-CPPT study; a group of 
individuals of both sexes subject to follow-up in the Fram-
ingham Study; and a group of men and women without 
coronary disease included in the LRCP Mortality Follow-up 
Study. The groups of men and women from the Framingham 
Study and the men from the LRCP-CPPT control group were 
divided into deciles, using a primary lipid end-point, and 
the deciles were subsequently divided into terciles using a 
secondary lipid end-point. When total cholesterol and LDL 
cholesterol were used as primary end-points, the total/HDL 
cholesterol and LDL/HDL cholesterol ratios identified 
significantly high- and low-risk groups within the deciles. 
For example, when the LRCP-CPPT men were divided into 
deciles according to LDL cholesterol, the absolute differ-
ence in risk within each decile between individuals in the 
upper and lower terciles of the total/HDL cholesterol ratio 
was 13% (95% confidence intervals [CI]: 8.2%–17.7%). The 
results were similar when the LDL/HDL cholesterol ratio 
was used. When the LDL/HDL cholesterol and total/HDL 
cholesterol ratios were used as primary end-points, neither 
total nor LDL cholesterol identified high- or low-risk groups 
within the deciles. These results of the stratified analysis 
were confirmed in the logistic regression analysis and sug-
gest that the total/HDL cholesterol ratio adds risk prediction 
power to total and LDL cholesterol values. However, no 
other lipid parameter adds predictive power to the total/HDL 
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Figure 2 impact of the apoB/apoA-i ratio on atherogenic balance.
Abbreviation: Apo, apolipoproteins.Vascular Health and Risk Management 2009:5 761
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cholesterol ratio. On the other hand, no conclusive data 
were obtained in relation to the superiority of the total/HDL 
cholesterol ratio over the LDL/HDL ratio, or vice versa. Only 
in women was the total/HDL cholesterol ratio found to have 
greater predictive power, which could be explained by the 
fact that this ratio, and not LDL/HDL cholesterol, includes 
triglyceride-rich lipoproteins in the numerator (VLDL and 
IDL), and triglycerides are a more powerful coronary risk 
predictor in women than in men.30 When there is no reliable 
calculation of LDL cholesterol, as occurs in individuals with 
serum triglycerides above 300 mg/dL (3.36 mmol/L), since 
in this scenario the Friedewald formula for estimating LDL 
cholesterol is not valid, the total/HDL cholesterol ratio will 
have to be used. The total/HDL cholesterol ratio was the best 
risk predictor in a subanalysis of the cohort of 14,916 men 
in the Physicians Health Study31 and, after adjusting for 
other factors, each unit increase in the ratio was found to 
be associated with a 53% increase in the risk of myocardial 
infarction. Similarly, in the cohort of  28,263 postmenopausal 
women undergoing a three-year follow-up in the Women’s 
Health Study,32 among lipid variables, various inflammation 
markers and homocysteine, the only independent predictors 
of risk for a cardiovascular event were C-reactive protein and 
the total cholesterol/HDL cholesterol ratio. Other studies33,34 
have shown the total cholesterol/HDL cholesterol ratio to be 
the lipid parameter with the greatest predictive power with 
regard to the presence, severity and extension of coronary 
atherosclerosis in women.
The total/HDL cholesterol ratio has also been shown to 
be a good predictor of carotid intima-media thickness; it has 
greater power than the isolated variables and similar power 
to that of the apoB/apoA-I ratio and non-HDL cholesterol.35 
More controversial is the role of the ratio between the 
principal protein fractions of LDL and HDL, apoB and A-I, 
which is the apoB/apoA-I ratio, as contradictory results 
regarding its use for predicting cardiovascular risk and its 
relative value compared with the LDL/HDL cholesterol 
and total/HDL cholesterol ratios have been obtained in the 
different observational studies.36,37 In the Interheart study, 
which included around 30,000 subjects from 52 countries, the 
apoB/apoA-I ratio was the variable which predicted a larger 
proportion of risk of myocardial infarction. Indeed, nearly 
50% of the population-attributable risk corresponded to that 
ratio.1 However, the Interheart study did not include any other 
lipid measurement, such as HDL or LDL cholesterol, and 
thus did not compare the relative usefulness of this ratio. In a 
recent study conducted in 3,322 Framingham inhabitants of 
both sexes with a 15-year follow-up, the apoB/apoA-I ratio 
was not superior to the total/HDL cholesterol ratio.38 In the 
EPIC-Norfolk study conducted in apparently healthy men 
and women, the apoB/apoA-I ratio was associated with the 
risk of future coronary events independently of the traditional 
lipid variables, including the total/HDL cholesterol ratio and 
the Framingham equation. However, the apoB/apoA-I ratio 
was not a better discriminatory factor between cases and 
controls than the total/HDL cholesterol ratio, and added little 
predictive power to the Framingham equation.39 Recently, 
the Cardiovascular Risk in Young Finns Study40 has demon-
strated that the apoB/apoA-I ratio measured in adolescence 
was higher than LDL/HDL cholesterol ratio in predicting 
increased carotid intima-media thickness in adulthood.
Considering these observations and given that apoli-
poprotein measurement methods are not as widely used as 
lipoprotein methods and the absence of consensus on refer-
ence values and therapeutic objectives, it would appear that 
the use of apoB/apoA-I ratio is limited for the time being.
Although the total/HDL cholesterol and LDL/HDL 
cholesterol ratios predict greater cardiovascular risk with a 
wide range of cholesterol or triglyceride concentrations, the 
risk is considerably higher in the presence of hypertriglyc-
eridemia. In the Helsinki study,41 the LDL/HDL cholesterol 
ratio was a powerful predictor of cardiovascular risk, mainly 
in subjects with elevated triglycerides. The greatest risk 
was observed in subjects with an LDL/HDL ratio 5 and 
triglycerides 200 mg/dL (2.24 mmol/L), who represented 
around 10% of the population studied; it was precisely this 
group which most benefited from treatment with gemfibrozil, 
with a remarkable 71% reduction in the incidence of coronary 
events, more than double that of the overall active-treatment 
group. In the cohort of 4,559 adult men in the PROCAM 
observational study,24,25 it was found that subjects with an 
LDL/HDL cholesterol ratio 5 presented more than six 
times the rate of coronary events of those with an LDL/HDL 
ratio 5; however, when the LDL/HDL cholesterol ratio 
was 5 and associated with triglycerides 200 mg/dL 
(2.24 mmol/L), the risk was double that of subjects with 
triglycerides 200 mg/dL (2.24 mmol/L). In the Physicians 
Health Study,31 this synergic effect was also found between 
the increase in the atherogenic/protective cholesterol ratio 
and hypertriglyceridemia.
Predicting the magnitude  
of the preventive effect
The total/HDL cholesterol and LDL/HDL cholesterol ratios 
are also good predictors of the degree of clinical benefit to be 
derived from lipid-lowering intervention.10 In the LRC-CPPT Vascular Health and Risk Management 2009:5 762
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with cholestyramine, the drops in the total/HDL cholesterol 
ratio in the active treatment group were associated with clini-
cal benefit. In the Helsinki study, multivariate analysis of the 
relationship between the lipid changes induced by gemfibrozil 
and the incidence of cardiovascular events in the treated group 
showed better predictive value for changes in HDL cholesterol 
and the total/HDL cholesterol ratio. In the placebo group of 
the AFCAPS/TexCAPS study,27 baseline LDL cholesterol 
had no predictive value for the incidence of coronary events, 
whereas predictive value was found in HDL cholesterol and 
the total/HDL cholesterol and LDL/HDL cholesterol ratios, 
both with greater significance than HDL cholesterol by 
adjusted logistic regression; in the active treatment group, 
only changes in apoB and the apoB/apoA-I ratio, which 
is largely equivalent to the LDL/HDL cholesterol ratio, 
predicted risk reduction. The total/HDL cholesterol ratio also 
had more predictive value than other lipid parameters in the 
control group of the 4S study;28 treatment-induced changes in 
this ratio were the best risk predictors in the group receiving 
simvastatin, with an estimated 17.6% risk difference for every 
one-unit reduction in the ratio.
In two angiographic studies in which cholestyramine 
was used as a hypolipidemiant agent,42,43 changes in the 
total/HDL cholesterol or LDL/HDL cholesterol ratios were 
the only independent predictors of the benefit observed in 
coronary stenosis. The predictive capacity of the ratios in this 
study is also supported by data indicating that an increase in 
HDL cholesterol is associated with an independent effect on 
regression,44 and that combined treatment with lipid-lowering 
agents which reduce LDL cholesterol or increase HDL 
cholesterol more than monotherapy would be associated with 
a net regression, in comparison with monotherapy, which 
would only slow down progression. In a meta-analysis of 
coronary atherosclerosis follow-up studies with intravascular 
ultrasound scans in patients treated with statins, the apoB/
apoA-I and HDL/LDL cholesterol ratios were powerful pre-
dictors of changes in atheroma burden.45 This analysis clearly 
shows that an increase in HDL cholesterol and apoA-I is 
fundamental, as is a reduction in LDL cholesterol and apoB, 
for halting progression of coronary atherosclerosis.
At least in secondary prevention, the predictive power 
of the ratios in relation to the benefit of intervention can be 
extended to countries with a lower prevalence of coronary 
disease such as Spain. In a cohort of 882 coronary patients 
included in the Hospital de Bellvitge Secondary Prevention 
Programme who were followed up for a mean of 34 months, 
those who reached the established therapeutic target, an 
LDL/HDL cholesterol ratio 3.7, or reduced ratio by 15%, 
reduced their risk of hospitalization for cardiovascular 
disease and death to less than half, compared with those who 
did not reach the target. Of the different lipid and nonlipid 
risk factors, reaching the LDL/HDL ratio objective had the 
greatest power to predict a favorable outcome in the mul-
tiple regression analysis adjusted for possible confounding 
factors.46
What do lipoprotein ratios provide 
that other conventional risk 
variables do not?
Classic cardiovascular risk factors such as age, sex, 
smoking, diabetes, hypertension, high LDL and low HDL 
cholesterol levels have been widely analyzed and estab-
lished as independent cardiovascular risk factors. Many 
other predictors, such as triglycerides, apoB, lipoprotein(a), 
homocysteine, C-reactive protein and others have also 
been studied. Furthermore, the total/HDL cholesterol and 
LDL/HDL cholesterol ratios are of great interest as major 
predictors of cardiovascular disease.
Guidelines for lipid management are based on LDL 
cholesterol concentrations, although other parameters 
including the total/HDL cholesterol index are better car-
diovascular risk predictors than LDL cholesterol and have 
not been included.47 The beneficial use of these indices as 
important cardiovascular risk predictors is based on multiple 
epidemiological studies which have shown that these ratios 
(total/HDL cholesterol and LDL/HDL cholesterol) have 
a greater correlation with cardiovascular disease and are 
therefore better predictors of cardiovascular disease than 
simple lipid parameters.5,31,48
A study in 32,826 menopausal women49 with an eight-year 
follow-up, after adjusting for age, smoking, C-reactive pro-
tein levels, homocysteine, body mass index, family history, 
diabetes, hypertension, physical activity, and alcohol 
consumption, found a relative risk of cardiovascular disease 
(95% CI) of  0.6 (0.5–0.8) for HDL cholesterol; 1.3 (1.0–1.5) 
for triglyceride levels; 1.4 (1.1–1.7) for LDL cholesterol; 
1.7 (1.4–2.1) for apoB concentration; 1.6 (1.3–1.9) for non-
HDL cholesterol; 1.5 (1.3–1.9) for the LDL/HDL cholesterol 
index; and 1.6 (1.3–1.9) for the total/HDL cholesterol index. 
The total/HDL cholesterol index is therefore a good predictor 
of cardiovascular risk irrespective of other factors.
In a retrospective study with a 20-year follow-up of 
1,439 men and 2,812 women with cardiovascular disease,50 
cardiovascular risk increased in relation to total/HDL 
cholesterol levels, regardless of total or LDL cholesterol. 
In men, the relative risk for quintile 5 over 1 of  LDL cholesterol Vascular Health and Risk Management 2009:5 763
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was 1.85, whereas the upper over the lower quintile of the 
total/HDL cholesterol ratio was 2.9. This cardiovascular risk 
difference between LDL cholesterol and total/HDL cholesterol 
was not found in women. The authors therefore conclude that 
men with elevated LDL cholesterol do not have to be treated 
aggressively if their total/HDL cholesterol index is low, and 
vice versa, with mild elevations of LDL cholesterol requiring 
more aggressive treatment if the total/HDL cholesterol ratio 
is high. This reveals that the total/HDL cholesterol ratio is an 
excellent cardiovascular risk predictor and a good parameter 
for deciding on the intensity and need for therapeutic interven-
tion in each different situation.
Other authors51 studying subjects with peripheral arterial 
disease demonstrated the importance of the total/HDL 
cholesterol index in predicting atherosclerosis in this 
setting. Studying a cohort of 2,265 subjects with a five-year 
follow-up, they found disease progression to be significantly 
related to smoking, the total/HDL cholesterol index and 
plasma levels of lipoprotein(a) and C-reactive protein.
In an analysis of the Framingham Heart Study and the 
Coronary Primary Prevention Trial data,52 LDL cholesterol 
and the total/HDL cholesterol and LDL/HDL cholesterol 
ratios were found to be good cardiovascular disease 
predictors. However, when vascular changes and cardiovas-
cular risk after intervention were studied, both ratios were 
better cardiovascular risk reduction predictors than total 
cholesterol or LDL cholesterol. These ratios should therefore 
be used when assessing vascular risk and in the reduction of 
such risk after therapeutic intervention.
There is reason to believe that these lipoprotein ratios, 
mainly total/HDL cholesterol, based on two values directly 
measured in a clinical laboratory and which indicate the 
relationship or proportion between the atherogenic and 
antiatherogenic lipid fraction, have predictive power for 
cardiovascular disease and cardiovascular risk reduction 
after intervention superior to that of classic lipid parameters 
and should be used in regular clinical practice.
With regard to identifying the “best” lipoprotein ratio, 
there is an interesting contrast between the use of cut-off 
points46 and quantiles.50 Thus it must be taken into account 
that while cut-off points can provide clinical relevant 
information, with regard to comparing ratios it would seem 
more logical to use quantiles within the cohort/population.
Conclusions and recommendations
LDL cholesterol concentration has been the prime index of 
cardiovascular disease risk and the main target for therapy. 
However, data now suggest that total/HDL cholesterol and 
LDL/HDL cholesterol ratios are risk indicators with greater 
predictive value than isolated parameters used independently, 
particularly the former. These two indices can be regarded 
as similar; since two thirds of plasma cholesterol are found 
in LDL, total and LDL cholesterol are closely correlated. 
The predictive capacity of these ratios is supported by data 
suggesting that an increase in HDL cholesterol is more 
prevalently associated with plaque regression, while a 
decrease in LDL cholesterol would slow down progression. 
Both predict greater cardiovascular risk for a wide range 
of cholesterol concentrations. However, when there is no 
reliable determination of LDL cholesterol, as in cases of 
hypertriglyceridemia, it is preferable to use the total/HDL 
cholesterol ratio. This may be particularly interesting in 
patients with features of the metabolic syndrome.
ApoB constitutes most of the protein content of LDL, 
as does apoA-I for HDL, even as parameters subject to less 
variation. Therefore, the apoB/apoAI ratio is also of great 
value for detecting atherogenic risk and often better than the 
total/HDL and LDL/HDL cholesterol ratios.
We suggest that future recommendations regarding the 
diagnosis and treatment of dyslipidemia, including instru-
ments for calculating cardiovascular risk or action guidelines, 
should include the lipoprotein ratios with greater predictive 
power which, in view of the results, are none other than those 
which include HDL cholesterol. Meanwhile, we propose that 
lipoprotein ratios should be routinely determined to assess 
the atherogeneity lipids disorders, mainly those characterized 
by an elevation in plasma triglycerides.
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